Therapeutic advances in Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a rare, inherited neurodegenerative disorder affecting movement, cognition, and behavior.
• The genetic cause of HD is known, and animal models reveal downstream intracellular issues.
• Despite extensive research, effective disease-modifying therapies for HD remain elusive.

Purpose of the Study:

• To review recent advancements in Huntington's disease research.
• To highlight novel strategies for slowing HD progression.
• To identify promising approaches for alleviating HD-related suffering.

Main Methods:

• Review of recent clinical trials and scientific literature on Huntington's disease.
• Analysis of therapeutic strategies targeting transcription, translation, and protein modification.
• Evaluation of palliative care options and their evidence base.

Main Results:

• Past clinical trials (e.g., coenzyme Q10, creatine) have not yielded disease-modifying therapies.
• Some agents (cysteamine, selisistat, hydroxyquinoline) show safety or efficacy, advancing to later trials.
• Palliative strategies for symptoms like chorea and irritability exist but lack robust evidence.

Conclusions:

• New therapeutic strategies targeting gene expression offer renewed hope for HD treatment.
• Further research is needed to develop effective disease-modifying treatments for Huntington's disease.
• Improving palliative care requires a stronger evidence base for symptom management.